[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"osteoarthritis-shoulder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:osteoarthritis-shoulder":242},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,41,68,97,121,146,169,204,230,251,271],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100629455","diaphragm-sparing-regional-anesthesia-techniques-for-shoulder-surgery-100629455",false,"NCT07474896","Diaphragm-Sparing Regional Anesthesia Techniques for Shoulder Surgery","Comparison of Interscalene Brachial Plexus Block Versus the Combination of Suprascapular and Infraclavicular Brachial Plexus Block for Shoulder Surgery: A Randomized Controlled Trial With Diaphragmatic Function Assessment","Inclusion Criteria:\n\n* Age ≥ 65 years\n* Elective shoulder surgery\n* ASA I-III\n* Planned use of regional anesthesia\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Allergy to local anesthetics\n* Planned continuous catheter technique\n* BMI \\>40 kg\u002Fm²\n* Coagulopathy or anticoagulation\n* Pre-existing phrenic nerve palsy\n* Neurological disorder of the operative limb\n* Pregnancy or breastfeeding\n* Participation in another clinical trial within 30 days","ALL","65 Years","100 Years",{"count":20,"type":21},70,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study will compare two regional anesthesia techniques for shoulder surgery and evaluate their effects on diaphragmatic function. The standard regional anesthesia technique for shoulder surgery is the interscalene brachial plexus block (ISB), which provides effective analgesia but is frequently associated with ipsilateral hemidiaphragmatic paresis due to phrenic nerve involvement.\n\nAn alternative diaphragm-sparing strategy is the combination of a suprascapular nerve block (SSNB) and an infraclavicular brachial plexus block (ICB), which may reduce the risk of diaphragmatic dysfunction while maintaining effective analgesia for shoulder surgery.\n\nAll participants will receive ultrasound-guided regional anesthesia prior to surgery and will be randomly assigned to one of two groups:\n\nGroup 1: Interscalene brachial plexus block Group 2: Suprascapular nerve block combined with infraclavicular brachial plexus block The primary aim of this study is to determine whether the diaphragm-sparing technique reduces the incidence of hemidiaphragmatic paresis while providing analgesia comparable to the standard interscalene block. Diaphragmatic movement will be assessed using ultrasound before and after block placement. Secondary outcomes include postoperative pain intensity, opioid consumption, pulmonary function parameters, and block-related complications.",[27],"Osteoarthritis Shoulder","RECRUITING","2026-05-20",{"date":31,"type":32},"2026-05-22","ACTUAL",{"date":34,"type":32},"2025-12-10",{"date":36,"type":21},"2027-01-31",{"name":38,"class":39},"Poznan University of Medical Sciences","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":67},"100444447","perform-humeral-system-study-100444447","NCT05067543","Perform Humeral System Study","PHS","Inclusion Criteria:\n\n* 18 years or older at the time of the informed consent or non-opposition (when applicable).\n* Informed and willing to sign an informed consent form approved by IRB or EC (when applicable).\n* Willing and able to comply with the requirements of the study protocol.\n* Considered a candidate for shoulder arthroplasty using a study device.\n* Meets indications for use requirements or other local, regional, or geographic specific regulatory requirements\n\nExclusion Criteria:\n\n* Not able to comply with the study procedures based on the judgment of the assessor (e.g. cannot comprehend study questions, inability to keep scheduled assessment times)\n* Patient belongs to a vulnerable group of patients, including minor patients, those unable to decide for themselves to participate or needing a Legally Authorized Representative (LAR), or others who could be subject to coercion (patients who may not be acting on their own initiative) (referred as \"vulnerable subject\" in the section 3.44 of the ISO 14155 norm).\n* Active local or systemic infection, sepsis, or osteomyelitis\n* Poor bone quality, where there could be considerable migration of the prothesis and\u002For a chance of fracture of the humerus or glenoid\n* Significant injury to the brachial plexus\n* Inadequate bone stock in the proximal humerus or glenoid fossa for supporting the components\n* Neuromuscular disease (e.g., joint neuropathy)\n* Patient with known allergy to one of the product materials\n* Metabolic disorders which may impair bone formation\n* Patient pregnancy\n* Planned for two-stage surgery","18 Years",{"count":50,"type":21},300,"OBSERVATIONAL","This study is an international, single arm, multicenter, prospective, non-significant risk, Post-Market Clinical Follow-up study, which is designed to collect safety and performance data at baseline, surgery, immediate post-op and annually through 10 years post-operation.\n\nData collected from this study will be used for purposes, including but not limited to, Post-Market Surveillance, peer-reviewed publications, education materials, regulatory submissions, and\u002For product development.",[27,54,55,56],"Avascular Necrosis","Post-traumatic Arthrosis of Other Joints, Shoulder Region","Rotator Cuff Tear Arthropathy","2026-02-19",{"date":59,"type":32},"2026-02-20",{"date":61,"type":32},"2021-09-12",{"date":63,"type":21},"2036-12-01",{"name":65,"class":66},"Stryker Trauma and Extremities","INDUSTRY",10,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":75,"targetDuration":77,"studyType":51,"phases":4,"briefSummary":78,"conditions":79,"keywords":82,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":96},"100522149","fx-shoulder-prospective-clinical-study-100522149","NCT06078865","FX Shoulder Prospective Clinical Study","FX Shoulder Post-Market Follow-Up Clinical Study","Inclusion Criteria:\n\nReceive an FX shoulder replacement medical device in accordance with the Indications for Use for the selected device system.\n\nExclusion Criteria:\n\nPatient who does not meet the inclusion criteria.",{"count":76,"type":21},600,"10 Years","Prospective Multi-Center Registry on study subjects with implanted devices marketed and legally commercialized in the USA by FX Shoulder Solutions.",[27,80,81],"Rotator Cuff Syndrome of Shoulder and Allied Disorders","Fracture, Shoulder",[83,84,85,86],"Osteoarthritis","Fracture","rotator cuff tear","shoulder trauma","2026-02-05",{"date":89,"type":32},"2026-02-09",{"date":91,"type":32},"2021-03-31",{"date":93,"type":21},"2031-12-30",{"name":95,"class":66},"FX Shoulder Solutions",4,{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":103,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":22,"phases":107,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":40},"100433886","phase-1-the-effect-of-micro-fragmented-adipose-tissue-mfat-on-shoulder-osteoarthritis-100433886","NCT04929951","The Effect of Micro Fragmented Adipose Tissue (MFAT) on Shoulder Osteoarthritis","Inclusion Criteria:\n\n* Age between 25 and 75 years-old\n* Diagnosis of pre-existing osteoarthritis of the glenohumeral joint\n* Working understanding of the English language and able to fully understand the procedure\n* Capable of providing informed consent\n* Able to complete online, in-person or phone surveys for the purposes of follow-up\n* Capable of understanding pre- and post-procedure care instructions\n* Ambulatory at baseline\n* Previous trial and failure of conservative therapy consisting of a minimum of 6 weeks of physical therapy and trial of anti-inflammatory medications if not contraindicated, with or without concomitant bracing and\u002For injections.\n\nExclusion Criteria:\n\n* Age \\\u003C 25 or \\> 75 years old\n* Radiographs demonstrating either no, little osteoarthritis, severe(bone on bone) osteoarthritis\n* Prior total or partial joint replacement surgery or surgery involving cartilage regeneration\n* Previous cortisone, PRP or Hyaluronic acid intra-articular injection within the last 3 months\n* Co-morbidity with the rheumatologic condition, inflammatory arthritis\n* Currently undergoing immunomodulatory therapy\n* Uncontrolled endocrine disorder\n* BMI \\>40 or joint space not visible by ultrasound\n* Current diagnosis of osteomyelitis, human immunodeficiency virus (HIV-1, -2) and\u002For hepatitis C (HCV), infection, and poorly controlled diabetes (HgA1C \\>7.0)\n* Pregnancy or planned pregnancy\n* previous stem cell injection into treatment joint\n* Patient scheduled to undergo any concomitant shoulder surgical procedures or other surgery which may affect outcomes.\n* Coagulopathy or anticoagulant treatment\n* Chronic pain involving multiple body parts or opioid medication management\n* Diagnosis of fibromyalgia\n* Concomitant massive(2 tendons with retraction), complete rotator cuff tendon tear","25 Years","75 Years",{"count":106,"type":21},48,[108],"PHASE1","This is a non-surgical trial comparing the clinical and functional outcomes of patients with osteoarthritis treated with Intra-articular injection of Micro Fragmented Adipose Tissue versus conventional therapy of intra-articular injection of corticosteroid.",[27,111],"Shoulder Pain","2025-10-28",{"date":114,"type":32},"2025-10-30",{"date":116,"type":32},"2022-07-28",{"date":118,"type":21},"2027-12-31",{"name":120,"class":39},"Stanford University",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":22,"phases":130,"briefSummary":131,"conditions":132,"keywords":133,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":40},"100572185","prophylactic-conjoint-tendon-lengthening-during-reverse-shoulder-arthroplasty-outcomes-100572185","NCT06729983","Prophylactic Conjoint Tendon Lengthening During Reverse Shoulder Arthroplasty Outcomes","Prophylactic Conjoint Tendon Lengthening During Reverse Shoulder Arthroplasty: is There a Difference in Anterior Shoulder Pain At One Year After Surgery?","Inclusion Criteria:\n\n* Patients who are at least 18 years old undergoing primary reverse total shoulder arthroplasty\n* Operations that occur at Loyola University Medical Center (Maywood, IL), Loyola Ambulatory Surgery Center (Maywood, IL), or Gottlieb Memorial Hospital\n\nExclusion Criteria:\n\n* Patients younger than 18 years old\n* Patients who had prior coracoid transfer procedure\n* Patients who are undergoing revision surgery from a prior arthroplasty\n* Current pregnancy As per standard protocol with all surgeries, a urine pregnancy test is performed prior to surgery. If positive, the surgery will be cancelled and the patient will be excluded from the research study.",{"count":129,"type":21},110,[24],"Some patients may experience persistent pain in the front of their shoulder after reverse shoulder replacement. One of the possible reasons for this is that the surgery causes a change in the alignment of the shoulder joint, which may cause increased tension and compression on one of the biceps tendon called the conjoint tendon. The purpose of this study is to evaluate whether conjoint tendon lengthening, a surgical procedure that involves cutting and lengthening the conjoint tendon in order to reduce tension and compression, is able to prevent or reduce the risk of anterior shoulder pain at one year after surgery.",[27],[134,135,136],"reverse shoulder athroplasty","conjoint tendon lengthening","pain outcome","2025-03-04",{"date":139,"type":32},"2025-03-07",{"date":141,"type":21},"2025-03",{"date":143,"type":21},"2029-03",{"name":145,"class":39},"Nickolas Garbis",{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":155,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":159,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":40},"100518582","denct-shoulder-bone-quality-evaluation-100518582","NCT06032416","DenCT Shoulder Bone Quality Evaluation","Collection of CT Images to Evaluate Bone Quality Before Total Shoulder Arthroplasty","Inclusion Criteria:\n\n* Patient must be older than 18 years and skeletally mature.\n* Patient must undergo the SHA, TSA, or RSA according to the Instructions for Use (IFU).\n* Patient must be anatomically and structurally suited to receive shoulder arthroplasty implants.\n* Patient is a candidate for lateral or bi-lateral shoulder arthroplasty due to one or more of the following:\n* Non-inflammatory degenerative joint disease including osteoarthritis.\n* Avascular necrosis of the humeral head.\n* Autoimmune disease including rheumatoid arthritis.\n* Irreparable rotator cuff tears.\n* Correction of functional deformity.\n* Patient must be able and willing to sign the IRB\u002FEC approved informed consent.\n* Patient must be able to undergo a preoperative CT scan\n* Patient must be willing to share their CT images with sponsor\n\nExclusion Criteria:\n\n* Patient is a candidate for shoulder arthroplasty due to one or more of the following:\n* Fractures of the proximal humerus, where other methods of treatment are deemed inadequate.\n* Revision TSA\u002FRSA after the prior TSA\u002FRSA.\n* Patient has experienced the traumatic fractures to the implant site.\n* Patient is unwilling or unable to give consent\n* Patient has any condition which would in the judgement of the Investigator, place the patient at undue risk or interfere with the study, e.g., any neuromuscular disease compromising the affected limb.\n* Patient is known to be pregnant or breastfeeding.\n* Patient is a vulnerable subject (prisoner, mentally incompetent or unable to understand what participation to the study entails, a known alcohol or drug abuser, and\u002For anticipated to be non- compliant).\n* Patient is uncooperative or patient with neurologic disorders who is incapable or unwilling to follow directions.\n* Patient has any sign of infection affecting the shoulder joint or in its proximity which may spread to the implant site.\n* Patient has rapid joint destruction, marked bone loss, or bone resorption apparent on roentgenogram.",{"count":154,"type":21},200,[24],"The objective of the study is to evaluate the preoperative bone quality assessment based on CT to later establish a scale for the decision of stemless shoulder arthroplasty.",[27,158],"Rotator Cuff Tears","NOT_YET_RECRUITING","2025-02-07",{"date":162,"type":32},"2025-02-10",{"date":164,"type":21},"2025-04",{"date":166,"type":21},"2027-04",{"name":168,"class":66},"Zimmer Biomet",{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":176,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":177,"targetDuration":179,"studyType":51,"phases":4,"briefSummary":180,"conditions":181,"keywords":190,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":203},"100552813","embo-registry-national-registry-for-artery-embolization-100552813","NCT06477965","Embo Registry; National Registry for Artery Embolization","Multicenter National Registry for Artery Embolization (Embo Registry) for the Treatment of Osteoarthritis and Areas of Localized Pain to Assess Treatment of Artery Embolization to Determine If Subjects Have Decrease Pain, Decreased Use of Narcotics and NSAIDs, and Quality of Life Improvement Post Procedure.","Inclusion Criteria:\n\n* \\> 18 years of age undergone artery embolization interventions for the treatment of chronic pain due to osteoarthritis or other diagnoses that cause localized pain.\n\nExclusion Criteria:\n\n* None",true,{"count":178,"type":21},1000,"12 Months","Embo Registry is a retrospective and prospective observational study to evaluate real world effectiveness and the use of Artery Embolization as a treatment for chronic pain with patients that have osteoarthritis and localized pain to provide symptomatic relief. This study is to determine the efficacy and validity of procedure and that following procedure patients had decreased pain and improved quality of life.",[182,183,184,27,185,186,187,188,189],"Chronic Pain","Osteoarthritis, Knee","Osteoarthritis Thumb","Pain, Chronic","Tendonitis Elbow","Tendonitis Shoulder","Tendonitis;Achilles","Tenosynovitis",[191,83,192,193,189],"Pain","Arthritis","Tendonitis","2024-10-24",{"date":196,"type":32},"2024-10-28",{"date":198,"type":32},"2024-07-15",{"date":200,"type":21},"2029-07-15",{"name":202,"class":39},"Vascular Solutions of North Carolina",2,{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":210,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":212,"targetDuration":4,"studyType":22,"phases":214,"briefSummary":215,"conditions":216,"keywords":217,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":40},"100476694","tsa-v-rsa-in-osteoarthritic-shoulders-with-greater-than-15-degrees-of-retroversion-100476694","NCT05487274","TSA v RSA in Osteoarthritic Shoulders With Greater Than 15 Degrees of Retroversion","Study Evaluating Reverse Versus Anatomic Total Shoulder Arthroplasty in Shoulders With Greater Than 15 Degrees of Retroversion in the Treatment of Osteoarthritis: Protocol","SERVASA15","Inclusion Criteria:\n\n1. Diagnosis of idiopathic shoulder OA.\n2. Patients who have failed standard non-surgical management of their shoulder OA who would benefit from a shoulder arthroplasty. Failed medical management will be defined as persistent pain and disability despite adequate standard non-operative management for at least 6 months. Medical management will be defined as: a) The use of drugs including analgesics and nonsteroidal anti-inflammatory drugs, b) Physiotherapy consisting of stretching, strengthening and local modalities (ultrasound, cryotherapy, etc.), c) Activity modification\n3. Imaging, and intra-operative findings confirming advanced glenohumeral cartilage loss\n4. Patients with a glenoid deficiency and \\>15 degrees of glenoid retroversion up to a maximum of 26 degrees of glenoid retroversion (i.e. -15.1, -17, -20…etc.)\n5. 65 years of age and older\n\nExclusion Criteria:\n\n1. Active joint or systemic infection\n2. Rotator cuff arthropathy\n3. Significant muscle paralysis\n4. Charcot's arthropathy\n5. Major medical illness (life expectancy less than 1 year or unacceptably high operative risk)\n6. Unable to understand the consent form\u002Fprocess\n7. Pregnancy\n8. Psychiatric illness that precludes informed consent\n9. Unwilling to be followed for the duration of the study\n10. Retroversion cannot be surgically corrected to within 10 degrees of neutral\n11. History of previous shoulder surgery on affected side\n12. Rheumatoid arthritis in the affected shoulder",{"count":213,"type":21},108,[24],"This study will compare total shoulder arthroplasty (TSA) with an augmented glenoid component and reverse shoulder arthroplasty (RSA) procedures, in participants with advanced glenohumeral osteoarthritis aged 65 years and older, who also present with greater than 15 degrees of glenoid retroversion, in the context of a prospective, randomized controlled trial to determine the optimal treatment in this patient population.",[27],[218,219,220],"Shoulder Arthroplasty","Glenohumeral Osteoarthritis","Idiopathic Osteoarthritis","2024-04-29",{"date":223,"type":32},"2024-04-30",{"date":225,"type":32},"2022-08-09",{"date":227,"type":21},"2029-12-31",{"name":229,"class":39},"Ottawa Hospital Research Institute",{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":237,"targetDuration":4,"studyType":22,"phases":239,"briefSummary":240,"conditions":241,"keywords":243,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":245,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":40},"100283232","tsa-techniques-in-glenohumeral-oa-100283232","NCT02966886","TSA Techniques in Glenohumeral OA","Comparison of Shoulder Arthroplasty Techniques in the Treatment of Glenohumeral Osteoarthritis: Protocol","Patient Population The target population is both men and women of any age with advanced osteoarthritis of the glenohumeral joint who are considered by the treating surgeon to be a candidate for shoulder replacement. The type of arthritic process will not be considered a deciding factor. The arthritis must be amenable to treatment using either a humeral head replacement (stemmed or stem-less), or a standard total shoulder replacement.\n\nInclusion Criteria\n\n1. Patients who have failed standard non-surgical management of their shoulder osteoarthritis who would benefit from a shoulder arthroplasty. Failed medical management will be defined as persistent pain and disability despite adequate standard non-operative management for 6 months. Medical management will be defined as:\n\n   1. The use of drugs including analgesics and non-steroidal anti-inflammatory drugs\n   2. Physiotherapy consisting of stretching, strengthening and local modalities (ultrasound, cryotherapy, etc.)\n   3. Activity modification\n2. Patients will present with a glenoid retroversion between 10-26 degrees.\n3. Imaging, and intra-operative findings confirming advanced humeral head cartilage loss, with or without glenoid cartilage loss.\n4. Age 18 years or older\n\nExclusion Criteria\n\n1. \\\u003C 10 degrees \u002F \\> 27 degrees of glenoid retroversion\n2. Active joint or systemic infection\n3. Rotator cuff arthropathy\n4. Significant muscle paralysis\n5. Charcot's arthropathy\n6. Major medical illness (life expectancy less than 1 year or unacceptably high operative risk)\n7. Unable to understand the consent form\u002Fprocess\n8. Pregnancy\n9. Psychiatric illness that precludes informed consent\n10. Unwilling to be followed for the duration of the study\n11. Retroversion cannot be surgically corrected to within 10 degrees of neutral\n12. History of previous shoulder surgery on affected side\n13. Rheumatoid arthritis in the affected shoulder",{"count":238,"type":21},216,[24],"Osteoarthritis (OA) of the shoulder is a disease resulting from the wearing down of cartilage over time. OA can produce pain and dysfunction at the affected joint and is a growing occurrence in an aging population. Total shoulder arthroplasty (TSA) is a surgical treatment used to treat patients with shoulder OA which involves replacing the worn-out ball and socket shoulder joint with prosthetic components. TSA is performed today with high success rates, however, complication rates associated with TSA remain prevalent particularly when the arthritis is associated with bone erosion on the glenoid (socket).\n\nGiven the high rate of revisions associated with TSA treatment in the setting of glenoid bone erosion, a number of surgical strategies have been developed. These surgical techniques include eccentric reaming which involves removing bone from the front of the socket, augmented glenoid component implantation, and posterior bone grafting to compensate for glenoid bone loss, and reverse shoulder arthroplasty. Few research studies have compared these different surgical techniques to one another. Previous studies have been limited to case series with small sample sizes and respective designs. This study is being conducted to determine which approach produces better outcomes. For the purpose of this study we will be comparing total shoulder arthroplasty techniques a) augmented glenoid component and eccentric reaming and b) augmented glenoid component and bone grafting in participants with advanced glenohumeral osteoarthritis.",[242],"Osteoarthritis, Shoulder",[244],"Surgical Management",{"date":223,"type":32},{"date":247,"type":32},"2017-04-23",{"date":249,"type":21},"2028-12",{"name":229,"class":39},{"id":252,"slug":253,"hasResults":11,"nctId":254,"briefTitle":255,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":257,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":258,"conditions":259,"keywords":260,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":203},"100522080","fx-shoulder-solutions-retrospective--prospective-clinical-study-100522080","NCT06077942","FX Shoulder Solutions Retrospective \u002F Prospective Clinical Study","Inclusion Criteria:\n\n* Received an FX Shoulder Solutions replacement medical device in accordance with the Indications for Use based upon surgeons' determination and standard of care for the selected device system beginning January 1, 2018, through June 30, 2023.\n\nExclusion Criteria:\n\n* Patient who does not meet the inclusion criteria above",{"count":76,"type":21},"Subjects implanted with the shoulder replacement medical devices manufactured by FX Shoulder Solutions and distributed by FX Shoulder Solutions.",[80,27,81],[83,261,84,262],"Roartator Cuff","Arthroplasty","2023-10-10",{"date":265,"type":32},"2023-10-12",{"date":267,"type":32},"2022-12-06",{"date":269,"type":21},"2032-12-30",{"name":95,"class":66},{"id":272,"slug":273,"hasResults":11,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":277,"eligibilityCriteria":278,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":22,"phases":280,"briefSummary":282,"conditions":283,"keywords":285,"overallStatus":159,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":40},"100396899","phase-2-autologous-adipose-tissue-derived-mesenchymal-stem-cells-admscs-for-osteoarthritis-100396899","NCT04448106","Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis","Clinical Study for Subjects With Osteoarthritis of Knees, Hips, and Shoulders Using a Combination of Intravenous Infusions With Intra-articular Injection of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs)","AdMSCs","Inclusion Criteria:\n\n* Age above 18 years\n* Male or female\n* Subjects in study group must have banked AdMSCs at Celltex (already passed communicable disease screen tests for HIV, syphilis and Hepatitis B and C during banking stage)\n* Must understand and voluntarily sign an Informed Consent for study participation obtained prior to undergoing any study-specific procedures\n* Must be diagnosed as OA-knees, OA-hips, or OA-shoulders by radiographic criteria and physical examination.\n\nExclusion Criteria:\n\n* Participation in another clinical study (with use of another Investigational Medical Product) within 3 months prior to study treatment start\n* Unwillingness or inability to comply with study procedures\n* Patients with serious basic diseases that affect survival, including blood diseases, cachexia, active bleeding, severe malnutrition, etc.\n* Clinically active malignant disease\n* Previous thrombotic disorder\n* History of known pulmonary embolism or known secondary anti-phospholipid syndrome\n* Known or suspected hypersensitivity to any components used to culture the AdMSCs, e.g. BSA and sulfur-containing products (e.g., DMSO)\n* Major trauma or surgery within 14 days of study treatment start\n* Mental condition rendering the subject (or the subject's legally acceptable representative\\[s\\]) unable to understand the nature, scope and possible consequences of the study\n* Alcohol, drug, or medication abuse within one year prior to study treatment start\n* Any condition that, in the Investigator's opinion, is likely to interfere with evaluation of the AdMSC therapy or satisfactory conduct of the study\n* Irreversible severe end-organ failure, such as heart failure\u002Fattack, stroke, liver and renal failure due to other disease conditions\n* Patients or family history with a hypercoagulable status, such as protein C\u002Fprotein S deficiency, factor V Leiden, prothrombin gene mutation, dysfibrinogenemia, etc.\n* History of long-term use of immunosuppressive agents\n* Organ transplants in the previous 6 months\n* Pregnant, breastfeeding, or desire to become pregnant or unwilling to practice birth control during participation in the study duration, unless surgically sterilized or postmenopausal during the study",{"count":50,"type":21},[281],"PHASE2","This is a phase 2 open-label, 6 arms (1 study group and 1 control group for each joint category), randomized control group clinical study with 300 subjects diagnosed with osteoarthritis of knees (n=100), hips (n=100) and shoulders (n=100). The study subjects will be evaluated for disease-associated severity according to symptoms, such as pain, mobility, daily active life, and functions using arthritis society established specific measurement tools related to the joints (KOOS and KSS for OA-knees: HOOS and HHS for OA-hips and ASES and CSS for OA-shoulders).",[183,284,27],"Osteoarthritis, Hip",[286],"Autologous Adipose-derived Stem Cells (AdMSCs)","2023-04-13",{"date":289,"type":32},"2023-04-18",{"date":291,"type":21},"2023-09-25",{"date":293,"type":21},"2026-08-15",{"name":295,"class":66},"Celltex Therapeutics Corporation"]